TY  - JOUR
A1  - Werner, Rudolf A.
A1  - Sayehli, Cyrus
A1  - Hänscheid, Heribert
A1  - Higuchi, Takahiro
A1  - Serfling, Sebastian E.
A1  - Fassnacht, Martin
A1  - Goebeler, Maria-Elisabeth
A1  - Buck, Andreas K.
A1  - Kroiss, Matthias
T1  - Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
JF  - European Journal of Nuclear Medicine and Molecular Imaging
N2  - No abstract available.
KW  - papillary thyroid carcinoma (PTC)
KW  - selpercatinib
KW  - radioiodine
KW  - combination
KW  - thyroid carcinoma (TC)
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324435
VL  - 50
IS  - 6
ER  - 
TY  - JOUR
A1  - Michalski, Kerstin
A1  - Schlötelburg, Wiebke
A1  - Hartrampf, Philipp E.
A1  - Kosmala, Aleksander
A1  - Buck, Andreas K.
A1  - Hahner, Stefanie
A1  - Schirbel, Andreas
T1  - Radiopharmaceuticals for treatment of adrenocortical carcinoma
JF  - Pharmaceuticals
N2  - Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established therapeutic concepts. Recent developments focus on targeting adrenal cortex-specific enzymes like the theranostic twin [\(^{123/131}\)I]IMAZA that shows a good image quality and a promising therapeutic effect in selected patients. But other established molecular targets in nuclear medicine such as the C-X-C motif chemokine receptor 4 (CXCR4) could possibly enhance the therapeutic regimen as well in a subgroup of patients. The aims of this review are to give an overview of innovative radiopharmaceuticals for the treatment of ACC and to present the different molecular targets, as well as to show future perspectives for further developments since a radiopharmaceutical with a broad application range is still warranted.
KW  - adrenocortical carcinoma
KW  - theranostics
KW  - endoradiotherapy
KW  - IMAZA
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-355901
SN  - 1424-8247
VL  - 17
IS  - 1
ER  - 
TY  - JOUR
A1  - Israel, Ina
A1  - Riehl, Gabriele
A1  - Butt, Elke
A1  - Buck, Andreas K.
A1  - Samnick, Samuel
T1  - Gallium-68-labeled KISS1-54 peptide for mapping KISS1 receptor via PET: initial evaluation in human tumor cell lines and in tumor-bearing mice
JF  - Pharmaceuticals
N2  - Kisspeptins (KPs, KISS1) and their receptor (KISS1R) play a pivotal role as metastasis suppressor for many cancers. Low or lost KP expression is associated with higher tumor grade, increased metastatic potential, and poor prognosis. Therefore, KP expression has prognostic relevance and correlates with invasiveness in cancers. Furthermore, KISS1R represents a very promising target for molecular imaging and therapy for KISS1R-expressing tumors. The goal of this study was to evaluate the developed KISS1-54 derivative, [\(^{68}\)Ga]KISS1-54, as a PET-imaging probe for KISS1R-expressing tumors. The NODAGA-KISS1-54 peptide was labeled by Gallium-68, and the stability of the resulting [\(^{68}\)Ga]KISS1-54 evaluated in injection solution and human serum, followed by an examination in different KISS1R-expressing tumor cell lines, including HepG2, HeLa, MDA-MB-231, MCF7, LNCap, SK-BR-3, and HCT116. Finally, [\(^{68}\)Ga]KISS1-54 was tested in LNCap- and MDA-MB-231-bearing mice, using µ-PET, assessing its potential as an imaging probe for PET. [\(^{68}\)Ga]KISS1-54 was obtained in a 77 ± 7% radiochemical yield and at a >99% purity. The [\(^{68}\)Ga]KISS1-54 cell uptake amounted to 0.6–4.4% per 100,000 cells. Moreover, the accumulation of [\(^{68}\)Ga]KISS1-54 was effectively inhibited by nonradioactive KISS1-54. In [\(^{68}\)Ga]KISS1-54-PET, KISS1R-positive LNCap-tumors were clearly visualized as compared to MDA-MB-231-tumor implant with predominantly intracellular KISS1R expression. Our first results suggest that [\(^{68}\)Ga]KISS1-54 is a promising candidate for a radiotracer for targeting KISS1R-expressing tumors via PET.
KW  - [\(^{68}\)]KISS1-54
KW  - KISS1 receptor
KW  - GPR54
KW  - kisspeptin
KW  - human tumor cell lines
KW  - positron emission tomography
KW  - PET
KW  - KISS1-54
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-355898
SN  - 1424-8247
VL  - 17
IS  - 1
ER  -